PUBLICATIONS


42. Nicolau DP, Nightingale CH, Tessier PR, Fu Q, Xuan DW, Esguerra EM, Quintiliani R. The Effect of Fleroxacin and Ciprofloxacin on the Pharmacokinetics of Multiple-Dose Caffeine. *Drugs* 1995;49(Suppl. 2):357-359.


103. Nie L, **Nicolau DP**, Tessier PR, Kourea HP, Browner BD, Nightingale CH. Use of a Bioabsorbable Polymer for the Delivery of Ofloxacin During


122. Richerson MA, Ambrose PG, Bui K, Grant E, Nicolau DP, Nightingale CH, Quintiliani R. Pharmacokinetic and Economic Evaluation of Piperacillin/Tazobactam Administered either as a Continuous or Intermittent


142. Freeman CD, **Nicolau DP**. Community-Acquired Pneumonia in Long-Term Care: The Other Community. *Consultant Pharmacist* 1999;11:1259-1273.


157. McNabb JC, Owens RC Jr., Xuan D, Quintiliani R, Nightingale CH, Nicolau DP. Comparison of Azithromycin Leukocyte Disposition in Healthy Volunteers versus...


204. Grant EM, **Nicolau DP.** Nightingale CH, Quintiliani R. Minimal of Interaction between Gatifloxacin and Oxycodone. *Journal Clinical Pharmacology* 2002;42(8):928-932.


219. Dandekar PK, Maglio D, Sutherland CA, Nightingale CH, **Nicolau DP**. Pharmacokinetic Profile of Meropenem 0.5g and 2g Administered as a 3 hour Infusion. *Pharmacotherapy* 2003;23(8):988-991.


Dr. David Nicolau’s Scholarship


320. Ong C, Kuti JL, Nicolau DP. Pharmacodynamic Modeling of Imipenem-Cilastatin, Meropenem, and Piperacillin-Tazobactam for Empiric Therapy of Skin


324. Ellis JM, Kuti JL, **Nicolau DP**. Pharmacodynamic Evaluation of Meropenem (MER) and Cefotaxime (CTX) for Pediatric Meningitis – A Report from the OPTAMA Program. *Pediatric Drugs* 2006;8(2):131-138.


329. DeRyke CA, Du X, **Nicolau DP**. Evaluation of Bacterial Kill when Modeling the Bronchopulmonary Pharmacokinetic Profile of Moxifloxacin and Levofloxacin...


ABSTRACTS


17a. Onyeji CO, Nicolau DP, Nightingale CH, Quintiliani R. Optimal duration of time above the minimum inhibitory concentration (Abstract No. 87). American Society for Microbiology, 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, Louisiana, October 1993

18a. Hitt CM, Patel KB, Nicolau DP, Nightingale CH. Effects of piperacillin/tazobactam on once-daily gentamicin pharmacokinetics. Thirteenth Annual Eastern States Conference for Pharmacy Residents and Preceptors, Baltimore, Maryland, April 1994


26a. Patel KB, Marangos MN, Nicolau DP, Nightingale CH. Synergistic activity of vancomycin or teicoplanin combined with streptomycin against VanB-type resistant enterococci with variable levels of Vm-resistance (Abstract No. 2). Connecticut Infectious Diseases Society, 10th Annual Meeting, Southbury, Connecticut, September 1994


30a. Patel KB, Marangos MN, Nicolau DP, Nightingale CH. Synergistic activity of vancomycin (Vm) or teicoplanin (Te) combined with streptomycin (Sm) against VanB-type resistant enterococci with variable levels of Vm-resistance (Abstract No. E100). American Society for Microbiology, 34th Interscience Conference on Antimicrobial Agents and Chemotherapy, Orlando, Florida, October 1994


32a. Onyeji CO, Nightingale CH, Tessier PR, Nicolau DP, Bow LM. Activities of clarithromycin, azithromycin and ofloxacin in combination with liposomal or unencapsulated GM-CSF against intramacrophage Mycobacterium avium-

33a. Nicolau DP, Marangos MN, Nightingale CH, Quintiliani R Jr., Courvalin P, Quintiliani R. Efficacy of vancomycin (Vm) and teicoplanin (Te) alone and in combination with streptomycin (Sm) in experimental enterococcal endocarditis (Abstract No. B73). American Society for Microbiology, 34th Interscience Conference on Antimicrobial Agents and Chemotherapy, Orlando, Florida, October 1994


35a. Nightingale CH, Belliveau PP, Nicolau DP, Quintiliani R. Streamlining antibiotic therapy in the hospital setting/cost containment by switching from parenteral to oral therapy (Abstract No. Is-100). 4th Western Pacific Congress of Chemotherapy and Infectious Diseases, Manila, Philippines, December 1994


37a. Klepser ME, Patel KB, Nicolau DP, Quintiliani R, Nightingale CH. Comparative activities of ofloxacin and ciprofloxacin combined with ceftazidime and piperacillin against Pseudomonas aeruginosa. The Role of Quinolones in Hospital Pharmacy, Poster symposium presented during American Society of Hospital Pharmacists, 29th Annual Midyear Clinical Meeting, Miami, Florida, December 1994


42a. Xuan D, **Nicolau DP**, DeVivo J, Tessier PR, Bow L, Quintiliani R, Nightingale CH. Endotoxin concentration reduction with the addition of 5S-IgG immunoglobulin in the presence of cefotaxime (Abstract No. 1290). 7th European Congress of Clinical Microbiology and Infectious Diseases, Vienna, Austria, March 1995


46a. **Nicolau DP**, Nightingale CH, Tessier PR, Fu Q, Xuan D, Esguerra EM, Quintiliani R. Effect of fleroxacin and ciprofloxacin on the pharmacokinetics of
caffeine (Abstract No. 3273). 19th International Congress of Chemotherapy, Montreal, Canada, July 1995


69a. Nicolau DP. Pharmacokinetic, Pharmacodynamic and Efficacy Considerations in Oral Cephalosporin Therapy Selection (Abstract No. S34). The Role of New Cephalosporins in Rational Antimicrobial Therapy. 8th European Congress of Clinical Microbiology and Infectious Diseases, Lausanne, Switzerland, May 1997


2). 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Ontario, Canada, September 28-October 1, 1997


89a. Nicolau DP, Lacy MK, McNabb JC, Quintiliani R, Nightingale CH. Continuous versus Intermittent Administration of Ceftazidime in Intensive Care Unit Patients


Antimicrobial Agents and Chemotherapy, San Francisco, California, September 26-29, 1999


124a. Kuti JL, Grant EM, Nicolau DP, Nightingale CH, Quintiliani R. Clinical Efficacy and Pharmacoeconomics of Piperacillin/Tazobactam Administered by Continuous versus Intermittent Infusion (Abstract RP-323). American Society of Health-


131a. Xuan D, Ye M, Nightingale CH, Nicolau DP. Pharmacokinetics of ABT-773, a New Semi-synthetic Ketolide in Neutropenic Lung-infected Mice: A Population
Dr. David Nicolau’s Scholarship


141a. Nicolau DP, Simpson IN, Urch JC. Oxapenem XOB (AM-114): In vitro activity alone and in combination with amoxycillin or cefaclor against community-acquired respiratory tract pathogens (Abstract No. 222). 12th European Congress of Clinical Microbiology and Infectious Disease, Milan, Italy, April 24-27, 2002


145a. Dandekar PK, Maglio D, Sutherland CA, Nightingale CH, Nicolau DP. Pharmacokinetics of Meropenem 0.5g and 2g Every 8h Administered as a 3h Infusion (Abstract No. A1-1388). 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, California, September 29, 2002


159a. O’Riordan TG, Chughtai BI, Nicolau D, Palmer LB. Gatifloxacin Levels in Airway Secretions of Patients with Ventilator-Associated Tracheobronchitis
Dr. David Nicolau’s Scholarship


191a. Ellis JM, Kuti JL, Nicolau DP. Pharmacodynamics of antimicrobials against Gram-negative bacteria in pediatric patients: a report from the OPTAMA Program (Abstract No. 266E). American College of Clinical Pharmacy, 2004 Annual Meeting, Dallas, TX, October 24-27, 2004


193a. Li C, Sutherland C, Nightingale CH, Nicolau DP. HPLC Determination of Tigecycline in Human Samples (Abstract No. 376b). World Conference - Dosing of Anti-Infectives, Nürnberg, Germany, September 9-11, 2004


202a. Sun HK, Kuti JL, Nicolau DP. Pharmacodynamics of Antimicrobials for the Empiric Treatment of Nosocomial Pneumonia: A Report from the OPTAMA Program (Abstract No. P902). 15th European Congress of Clinical Microbiology and Infectious Diseases, Copenhagen, Denmark, April 2-5, 2005

204a. Ludwig E, Maglio D, Konkoly-Thege M, Kuti J, Nicolau D. Pharmacodynamic comparison of intravenous antimicrobials against Pseudomonas aeruginosa in Hungarian hospitals - A report from the OPTAMA Program (Abstract No. P904). 15th European Congress of Clinical Microbiology and Infectious Diseases, Copenhagen, Denmark, April 2-5, 2005

205a. Jones ME, Nicolau DP, Kuti JL, Nightingale C, Draghi DC, Flamm RK, Sahm DF. Activity and pharmacodynamics of RO490-8463 (CS-023), a carbapenem with activity against MRSA (Abstract No. P1573). 15th European Congress of Clinical Microbiology and Infectious Diseases, Copenhagen, Denmark, April 2-5, 2005


207a. Ellis JM, Kuti JL, Nicolau DP. Pharmacodynamics of Meropenem (MER) and Cefotaxime (CTX) for Pediatric Meningitis – A Report from the OPTAMA Program (Abstract No. 513). Pediatric Academic Societies’ Annual Meeting, Washington, DC, May 14–17, 2005


217a. DeRyke CA, Xu D, Nicolau DP. Evaluation of Bacterial Kill when Modeling the Bronchopulmonary Pharmacokinetic Profile of Moxifloxacin (MOX) and


221a. Kiffer CRV, Mendes C, Eagye KJ, Kuti JL, Nicolau DP. Pharmacodynamic comparison of three carbapenems against extended spectrum Beta-lactamase (ESBL) producing \textit{Escherichia coli} and \textit{Klebsiella} spp from the MYSTIC Program in Brazil. (Abstract No. P1550). 16\textsuperscript{TH} European Congress of Clinical Microbiology and Infectious Diseases, Nice, France, April 2006

222a. Stein GE, Schooley S, Nicolau DP. Urinary Bactericidal Activity of Levofloxacin (750mg) against Fluoroquinolone-Resistant Uropathogens. (Abstract No. P1533). 16\textsuperscript{TH} European Congress of Clinical Microbiology and Infectious Diseases, Nice, France, April 2006


Dr. David Nicolau’s Scholarship


Dr. David Nicolau’s Scholarship


237a. Lee SY, Fan HW, **Nicolau DP**. Antibacterial Effects of Moxifloxacin and Levofloxacin Simulating Epithelial Lining Fluid Concentrations against Community-Acquired Methicillin-Resistant *Staphylococcus Aureus* (CA-MRSA). (Abstract No. P2-027). 10th Western Pacific Congress on Chemotherapy and
Infectious Diseases, Fukuoka International Congress center, Fukuoka, Japan, December 3-6, 2006


277a. Bulik CC, Fauntleroy KA, Jenkins SG, **Nicolau DP**, Kuti JL. Comparison of Meropenem (MEM) MICs for Carbapenemase producing *Klebsiella pneumoniae* (KPC) by E-Test, Broth Microdilution (BMD), and VITEK 2 Methods. (Abstract


284a. Bulik CC, Christensen H, Nicolau DP. In Vitro Activity of CXA-101, a Novel Cephalosporin, Against Resistant Phenotypes of Pseudomonas aeruginosa (PSA).
285a. Crandon JL, Sutherland C, Nicolau DP. Doripenem remains stable up to 10 days under refrigeration and at least 28 days in the freezer. (Abstract No. 6-047). American Society of Hospital Pharmacists, 44th Annual Midyear Clinical Meeting, Las Vegas, NV, December 2009


298a. Bulik CC, Tessier PR, Keel RA, Sutherland CA, Nicolau DP. In Vivo Efficacy of Human Simulated CXA-101 ± Tazobactam versus Piperacillin-Tazobactam


304a. Mazzei T, Breilh D, Mutters R, Kuti JL, **Nicolau DP**. Carbapenem Pharmacodynamics (PD) against *Pseudomonas* and *Acinetobacter* Isolated from Intensive Care Units in European Hospitals: Results from the 2009 PASSPORT Program. (Abstract No. 1118). 23rd Annual Congress of the European Society of Intensive Care Medicine (ESICM), Barcelona, Spain, October 9-13, 2010

305a. Bulik CC, Wiskirchen DE, Sutherland CA, Kuti JL, **Nicolau DP**. Concentration Dependent Protein Binding of Tigecycline in Adult Diabetic Patients. (Abstract No. 199). American College of Clinical Pharmacy, 2010 Annual Meeting, Austin, TX, October, 2010
306a. Eagye KJ, **Nicolau DP**. Fluoroquinolone Use Is Not Associated with Change in Imipenem Susceptibility of Pseudomonas aeruginosa in 25 Hospitals over 9 Years. (Abstract No. 3737). 48th Annual Meeting of the Infectious Diseases Society of America (IDSA), October, Vancouver, British Colombia, Canada, 2010


308a. Keel RA, Kuti JL, Sahm DF, **Nicolau DP**. Pharmacodynamic Target Attainment Rates for 6 Antibiotics against Pseudomonas aeruginosa Isolates in USA Hospitals. (Abstract No. 2514). 48th Annual Meeting of the Infectious Diseases Society of America (IDSA), Vancouver, British Colombia, Canada, October 2010


313a. Wilde AM, Nailor MD, **Nicolau DP**, Kuti JL. Validation of a Ventilator Associated Pneumonia (VAP) Clinical Pathway using Quantitative
Bronchoalveolar Lavage (BAL) for Diagnosis. (Abstract No. 15). 29th Connecticut Infectious Diseases Society Meeting & Symposium, Yale University West Campus, Orange, CT, May 2011


323a. Housman ST, Sutherland CA, Nicolau DP. In Vitro Potency of Rib-X Novel Compounds against Respiratory Pseudomonas aeruginosa isolates. (Abstract No. XXX). 49th Annual Meeting of the Infectious Diseases Society of America (IDSA), Boston, Ma, October 20-23, 2010


325a. Crandon JL, Banevicius MA, Nicolau DP. Comparative Potency of Ceftazidime (CAZ) and Ceftazidime-NXL104 (CAZ104) against a Resistant Population of Clinical Pseudomonas aeruginosa (PSA) Isolates. (Abstract No. 858). 49th Annual Meeting of the Infectious Diseases Society of America (IDSA), Boston, Ma, October 20-23, 2010